戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 osan, methyl salicylate, sodium fluoride and povidone, against two important proteases of SARS-CoV-2
2 n spectra, revealing direct contacts between povidone and the API.
3 to include use of a sterile lid speculum and povidone iodine (5%).
4 yes using topical 0.1% amphotericin B and 5% povidone iodine (P = .008 and .021, respectively).
5 icidal activity of various concentrations of povidone iodine (PI) solution in an agar plate experimen
6 ageenan (Carr-NS), nitric oxide (NO-NS), and povidone iodine (PI-NS).
7 l activity of 0.12% chlorhexidine (CHX), 10% povidone iodine (PVD), Vega oral care gel (VEGA), and an
8  Patients were 32.7% and 33.9% female in the povidone iodine and chlorhexidine gluconate groups, resp
9 f patients was 65.0 years (39.0-79.0) in the povidone iodine group and 65.0 years (41.0-78.0) in the
10 were identified in 80 patients (5.1%) in the povidone iodine group vs 97 (5.5%) in the chlorhexidine
11                                              Povidone iodine in alcohol as preoperative skin antiseps
12 d are non-irritating, unlike preparations of povidone iodine in our assays.
13 dition of topical 0.1% amphotericin B and 5% povidone iodine might be optional effective regimens for
14 e randomly assigned each month to either use povidone iodine or chlorhexidine gluconate, each formula
15              The choice of antiseptic agent, povidone iodine or chlorhexidine gluconate, remains deba
16 hexidine gluconate plus alcohol vs 6.5% with povidone iodine plus alcohol); maintaining normothermia
17  investigates the efficacy of nasopharyngeal povidone iodine solutions in reducing the viral load of
18                            Lid speculum use, povidone iodine strength (5% vs. 10%), injection locatio
19 r periods) were randomly assigned to receive povidone iodine vs 1762 patients (26 cluster periods) to
20 , SSIs were present in 4.2% of patients with povidone iodine vs 3.3% with chlorhexidine gluconate (re
21 inal surgery, SSIs were present in 6.8% with povidone iodine vs 9.9% with chlorhexidine gluconate (re
22             The unadjusted relative risk for povidone iodine vs chlorhexidine gluconate was 0.92 (95%
23 reparation wipes (alcohol, chlorhexidine and povidone iodine) and found that during wiping they reduc
24  was swept with a culture swab before use of povidone iodine; the inferior fornix of the fellow eye w
25 sinfection with polyvinylpyrrolidone (PVP or povidone)-iodine-alcohol and the correlation with postop
26 uction was observed after the application of povidone-iodine (log(10) 3.68 +/- 0.69 at 5 min; log(10)
27  assigned to receive oropharyngeal care with povidone-iodine (n = 91) or placebo (n = 88) six times d
28                                        While povidone-iodine (PI) is a commonly used antiseptic solut
29                                              Povidone-iodine (PI) is the current gold standard for an
30                                      Topical povidone-iodine (PI) is widely used as an ocular surface
31                                              Povidone-Iodine (PI) may be diluted when used as an anti
32 y aims to investigate the effect of diluting povidone-iodine (PI) on bacterial growth from bacterial
33 nts followed a pre-IVI asepsis protocol with povidone-iodine (PI).
34 plants were exposed to three antimicrobials: povidone-iodine (PovI; 0.05%, 1%, and 5%), chlorhexidine
35                      Chlorhexidine (CHX) and povidone-iodine (PVI) are used for skin antisepsis, mini
36 al was conducted to test the hypothesis that povidone-iodine (PVI) irrigation versus no irrigation (N
37                                              Povidone-iodine (PVI) is principally used as an antimicr
38 es suggested that compared with tears, after povidone-iodine (PVP-I) alone (2 studies, 409 participan
39 This review article addresses the effects of povidone-iodine (PVP-I) and its utility in the treatment
40              A pre-IVI asepsis protocol with povidone-iodine (PVP-I) was applied.
41 ) for presumed cure among those treated with povidone-iodine (vs antibiotics) was 1.46 in the Philipp
42 ant difference between the effect of topical povidone-iodine 1.25% and topical antibiotics commonly a
43                                   To compare povidone-iodine 1.25% ophthalmic solution with topical a
44                                              Povidone-iodine 1.25%, which is widely available and ine
45 preparation for intravitreal injection using povidone-iodine 5% alone in the absence of postinjection
46                      The preoperative use of povidone-iodine 5% and the postoperative use of impregna
47 paration consisted of topical anesthetic and povidone-iodine 5% without the use of preinjection or po
48                      The preoperative use of povidone-iodine 5%, dilute intracameral antibiotics (via
49 cohol was significantly more protective than povidone-iodine against both superficial incisional infe
50 .5 to 0.7 days) and in India was 12 days for povidone-iodine and 17 days for ciprofloxacin (95% CI, -
51 sumed cure in the Philippines was 7 days for povidone-iodine and 7 days for neomycin-polymyxin B-gram
52 opriate wound construction, a combination of povidone-iodine and antibiotics provide a reasonable app
53                             Continued use of povidone-iodine and consideration to eliminate topical a
54 ement: The subxyphoid area was cleansed with povidone-iodine and draped.
55 very surgical facility, including periocular povidone-iodine and intracameral moxifloxacin.
56 ng intravitreous injections with and without povidone-iodine and rates with and without topical antib
57  doxycycline, 100 mg for 2 weeks; 3) topical povidone-iodine and systemic doxycycline, 100 mg for 2 w
58                 Objective: To assess whether povidone-iodine application at the end of adjustable sut
59 echanical debridement measures with adjuvant Povidone-iodine application with and without systemic an
60 echanical debridement measures with adjuvant povidone-iodine application with and without systemic an
61 s for repair of cardiac defects and received povidone-iodine as a preoperative antiseptic.
62 eive a nasal antiseptic solution, containing povidone-iodine as the main ingredient, (n = 25) or a co
63  This study was not able to demonstrate that povidone-iodine at the end of adjustable suture strabism
64 was to test the hypothesis that preoperative povidone-iodine contributes to postoperative thyroid dep
65 ine washcloths and oral rinse and intranasal povidone-iodine decreased the SSI rate by more than 50%
66                                              Povidone-iodine demonstrated greater ocular surface disc
67                Interventions: One drop of 5% povidone-iodine directly over the sliding noose of the a
68                    Over a 5-year period, for povidone-iodine drops before performing intravitreal inj
69 xidine-alcohol is superior to cleansing with povidone-iodine for preventing surgical-site infection a
70 de, 0.12% chlorhexidine digluconate, or 7.5% povidone-iodine for subgingival irrigation during SRP.
71  the chlorhexidine-alcohol group than in the povidone-iodine group (9.5% vs. 16.1%; P=0.004; relative
72 eumonia occurred in 24 patients (31%) in the povidone-iodine group and 20 (28%) in the placebo group
73 acheobronchitis: eight patients (10%) in the povidone-iodine group and five patients (7%) in the plac
74 ss syndrome occurred in five patients in the povidone-iodine group but not in the placebo group (p =
75                                          The povidone-iodine group had the highest clinical improveme
76 e chlorhexidine-alcohol group and 440 in the povidone-iodine group) qualified for the intention-to-tr
77 tion-to-treat population) was 150 (78 in the povidone-iodine group, 72 in the placebo group).
78 ares favorably with previous series in which povidone-iodine has been used.
79 e regarding the risk of endophthalmitis when povidone-iodine is not used before intravitreous injecti
80  only a small number of eyes did not receive povidone-iodine just prior to an intravitreous injection
81 onic debridement, STC and GPAP with adjuvant Povidone-iodine led to significant clinical improvements
82 nic debridement, STC, and GPAP with adjuvant povidone-iodine led to significant clinical improvements
83                           Likewise, multiuse povidone-iodine may allow for large relative cost reduct
84 tion shields for pulmonary artery catheters; povidone-iodine ointment applied to insertion sites of h
85 acterial keratitis to topical treatment with povidone-iodine or antibiotics (neomycin-polymyxin B-gra
86 milar analyses were performed for a multiuse povidone-iodine protocol for intravitreal injections.
87                  Preoperative application of povidone-iodine remains the standard protocol for the pr
88 n with either chlorhexidine-alcohol scrub or povidone-iodine scrub and paint.
89 orhexidine skin cleanser was substituted for povidone-iodine solution during initial aseptic preparat
90 hexidine washcloths and oral rinse and nasal povidone-iodine solution to be used the night before and
91 e effective for catheter insertion care than povidone-iodine solutions to prevent catheter-associated
92 e is no evidence to recommend oral care with povidone-iodine to prevent ventilator-associated pneumon
93 rgery is not well defined, and the effect of povidone-iodine use on suture colonization is unknown.
94                        No adverse effects of povidone-iodine were observed.
95 0% isopropyl alcohol, tincture of iodine, or povidone-iodine with 70% ethyl alcohol (i.e., Persist).
96 1 (with povidone-iodine) or group 2 (without povidone-iodine) at the end of surgery.
97 ing assigned participants into group 1 (with povidone-iodine) or group 2 (without povidone-iodine) at
98 ation rates were determined to be 2.93% with povidone-iodine, 2.58% with tincture of iodine, 2.50% wi
99       Skin antisepsis was performed with 10% povidone-iodine, 70% isopropyl alcohol, tincture of iodi
100  28773 injections (3120 eyes) performed with povidone-iodine, 9 cases of endophthalmitis occurred: 6
101 nd listed on the ClinicalTrials.gov website: povidone-iodine, chlorhexidine, hydrogen peroxide, cyclo
102 tication (P/D) and hyperthermic intrapleural povidone-iodine, prophylactic chest wall radiotherapy an
103 AP) and a repeated submucosal application of Povidone-iodine.
104 P), and a repeated submucosal application of povidone-iodine.
105 er 12 months (P = 0.045 and P = 0.002) using povidone-iodine.
106 ght benefit seemed to derive from the use of povidone-iodine.
107 is more protective against infection than is povidone-iodine.
108 of iodine rather than isopropyl alcohol plus povidone-iodine.
109 rom 2 participants were administered without povidone-iodine; both participants developed endophthalm
110 re divided into two groups: Group 1 received povidone-iodine; group 2 received chlorhexidine as a top

 
Page Top